Gold prices tick higher on fresh U.S. tariff threats, Fed rate cut hopes
Investing.com - RBC Capital lowered its price target on Inspire Medical (TASE:BLWV) Systems (NYSE:INSP) to $180.00 from $215.00 on Tuesday, while maintaining an Outperform rating on the stock. The medical device company, currently valued at $2.24 billion, maintains a strong financial health score of "GREAT" according to InvestingPro analysis.
The price target reduction follows Inspire Medical’s second-quarter revenue beat of 2% and a significant guidance reduction for 2025, which the company now considers a transition year due to slower-than-expected Inspire V product ramp. Despite near-term challenges, the company maintains impressive fundamentals with an 84.65% gross margin and robust revenue growth of 27.11% over the last twelve months.
Inspire Medical lowered its 2025 revenue guidance by approximately $43 million, representing a 5% reduction to 12-13% year-over-year growth, and reduced its adjusted earnings per share guidance by 53% to $1.00-1.10.
The guidance reduction triggered a 21% drop in Inspire Medical shares in after-market trading, with RBC noting that investors will likely remain on the sidelines until business momentum improves.
Despite the near-term challenges, RBC maintained its Outperform rating on Inspire Medical, stating that the company’s long-term growth story remains intact, though momentum may not be proven until fourth-quarter earnings.
In other recent news, Inspire Medical Systems has faced several significant developments. The company reported second-quarter results that showed revenue slightly ahead of market expectations. However, Inspire Medical Systems has reduced its 2025 revenue guidance to $900-910 million, down from the prior range of $940-955 million. This guidance cut has led to a series of analyst downgrades. Truist Securities downgraded the stock from Buy to Hold, citing growth concerns related to the Inspire V product and cut its price target to $125.00 from $190.00. Similarly, Stifel lowered its price target to $140.00 while maintaining a Hold rating, noting lagging facility activations. Mizuho (NYSE:MFG) also reduced its price target to $170.00, maintaining an Outperform rating, following the company’s lowered full-year guidance. The adjusted earnings per share outlook was also cut to $1.00-$1.10 from the previous $2.20-$2.30. KeyBanc joined the downgrades, moving its rating to Sector Weight despite the revenue exceeding expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.